We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+27.43%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$197M
AUM Growth
-$76M
(-28%)
Cap. Flow
-$97.6M
Cap. Flow
% of AUM
-49.58%
Top 10 Holdings %
Top 10 Hldgs %
44.5%
Holding
160
New
26
Increased
14
Reduced
15
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ATXS
Astria Therapeutics
ATXS
|
+$9.39M |
| 2 |
Tandem Diabetes Care
TNDM
|
+$4.07M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
+$3.73M |
| 4 |
Outlook Therapeutics
OTLK
|
+$3.62M |
| 5 |
Replimune Group
REPL
|
+$3.32M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$8.27M |
| 2 |
Insmed
INSM
|
+$5.77M |
| 3 |
MBTC
Nocturne Acquisition Corporation Ordinary Shares
MBTC
|
+$5.17M |
| 4 |
BioAtla
BCAB
|
+$4.26M |
| 5 |
Illumina
ILMN
|
+$4.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.67% |
| 2 | Financials | 5.8% |
| 3 | Communication Services | 0.42% |
| 4 | Industrials | 0.36% |
| 5 | Materials | 0.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ATXS
1
DELISTED
Astria Therapeutics
ATXS
| $20.2M | 10.26% |
1,355,372
+910,372
| +205% | +$9.39M |
|
2
ADMA Biologics
ADMA
$2.01B
| $11.1M | 5.66% |
2,870,000
-13,710
| -0.5% | -$42.3K |
|
|
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $10.1M | 5.13% |
385,000
-140,000
| -27% | -$3.1M |
|
|
BLU
4
DELISTED
BELLUS Health Inc.
BLU
| $9.31M | 4.73% |
1,132,000
| – | – |
|
|
PEPL
5
DELISTED
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
| $7.5M | 3.81% |
735,000
| – | – |
|
|
AKRO
6
DELISTED
Akero Therapeutics
AKRO
| $6.85M | 3.48% |
125,000
-15,000
| -11% | -$643K |
|
|
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
| $6.43M | 3.27% |
1,025,000
-725,000
| -41% | -$2.76M |
|
|
VRNA
8
DELISTED
Verona Pharma
VRNA
| $5.62M | 2.86% |
215,000
-189,000
| -47% | -$2.52M |
|
|
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.29M | 2.69% |
100,000
| – | – |
|
|
10
Amylyx Pharmaceuticals
AMLX
$2.15B
| $5.17M | 2.63% |
140,000
+105,000
| +300% | +$3.73M |
|
11
Rhythm Pharmaceuticals
RYTM
$7.36B
| $4.95M | 2.52% |
170,000
| – | – |
|
|
ACLX
12
DELISTED
Arcellx
ACLX
| $4.65M | 2.36% |
150,000
+35,000
| +30% | +$803K |
|
|
13
Replimune Group
REPL
$426M
| $4.35M | 2.21% |
+160,000
| New | +$3.32M |
|
|
KRTX
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $4.32M | 2.2% |
22,000
+5,000
| +29% | +$1.07M |
|
15
Xtant Medical Holdings
XTNT
$59.1M
| $4.12M | 2.1% |
6,246,291
| – | – |
|
|
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.07M | 2.07% |
190,000
+65,000
| +52% | +$1.39M |
|
|
17
Tandem Diabetes Care
TNDM
$1.23B
| $4.05M | 2.06% |
+90,000
| New | +$4.07M |
|
18
Glaukos
GKOS
$9.19B
| $3.97M | 2.02% |
91,000
-6,000
| -6% | -$296K |
|
|
ESPR
19
DELISTED
Esperion Therapeutics
ESPR
| $3.86M | 1.96% |
620,000
-39,869
| -6% | -$285K |
|
|
20
Outlook Therapeutics
OTLK
$196M
| $3.59M | 1.83% |
+166,370
| New | +$3.62M |
|
21
ResMed
RMD
$30.9B
| $3.54M | 1.8% |
17,000
| – | – |
|
|
AKYA
22
DELISTED
Akoya BioSciences
AKYA
| $3.16M | 1.6% |
330,000
+34,000
| +11% | +$418K |
|
23
Quanterix
QTRX
$161M
| $3.11M | 1.58% |
224,800
+129,800
| +137% | +$1.49M |
|
24
Myriad Genetics
MYGN
$485M
| $3.08M | 1.56% |
212,000
+26,000
| +14% | +$484K |
|
25
KORU Medical Systems
KRMD
$186M
| $3.05M | 1.55% |
855,000
-140,500
| -14% | -$387K |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Altium Capital Management held 160 positions worth $197M, down 28% from $273M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Altium Capital Management withdrew a net $97.6M in Q4 2022, closing 66 positions and reducing 15 holdings. Its most notable exit was ChemoCentryx, Inc., an estimated $8.27M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 79% a quarter earlier, followed by Financials and Communication Services.
Against the trend, Altium Capital Management opened a new position in Tandem Diabetes Care worth $4.05M.
- Altium Capital Management's largest Q4 2022 buy was Tandem Diabetes Care: 90,000 shares worth $4.05M.
- Altium Capital Management added most to Astria Therapeutics in Q4 2022, an estimated $9.39M increase.
- Altium Capital Management's biggest Q4 2022 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $3.1M.
- Altium Capital Management fully exited ChemoCentryx, Inc. in Q4 2022, selling an estimated $8.27M.
- Altium Capital Management's ten largest holdings make up 45% of its $197M portfolio in Q4 2022.
- Altium Capital Management opened 26 new positions and closed 66 in Q4 2022.
- Altium Capital Management's portfolio value fell 28% quarter-over-quarter to $197M.
Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.